Comparative Pharmacology
Head-to-head clinical analysis: NALOXONE HYDROCHLORIDE AUTOINJECTOR versus NARCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALOXONE HYDROCHLORIDE AUTOINJECTOR versus NARCAN.
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) vs NARCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Opioid receptor antagonist; binds competitively to mu, kappa, and delta opioid receptors, reversing opioid effects.
Initial: 0.4 mg or 2 mg intramuscularly (IM) or subcutaneously (SC); may repeat every 2-3 minutes as needed. For autoinjector: 2 mg single dose, administer IM or SC into anterolateral thigh; may repeat every 2-3 minutes with a new device if no response. Max total dose: 10 mg.
Initial dose: 0.4 mg to 2 mg IV, IM, or SC, repeated every 2 to 3 minutes as needed. For opioid-induced respiratory depression, may use 0.1 to 0.2 mg IV increments in patients with opioid dependence to avoid withdrawal.
None Documented
None Documented
Terminal elimination half-life approximately 1 to 1.5 hours in adults. In neonates, half-life is prolonged (about 3 hours). Clinical context: due to short half-life, repeated doses or continuous infusion may be needed for opioid overdose with long-acting opioids.
Approximately 1 hour in adults; context: shorter than most opioids (e.g., morphine 2-4 h), necessitating repeated doses for prolonged opioid effects.
Primarily hepatic metabolism (glucuronidation) followed by renal excretion of metabolites. Less than 1% excreted unchanged in urine. Fecal excretion minimal (<5%).
Primarily hepatic metabolism (glucuronidation) followed by renal excretion of metabolites; <5% excreted unchanged in urine.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist